Short Interest Summary: Calithera Biosciences Incorporated (NASDAQ:CALA) Sellers Increased By 0.81% Their Shorts

November 28, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Summary: Calithera Biosciences Incorporated (NASDAQ:CALA) Sellers Increased By 0.81% Their Shorts

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.81% in short interest. CALA’s total short interest was 1.10M shares in November as published by FINRA. Its up 0.81% from 1.09 million shares, reported previously. With 222,200 shares average volume, it will take short sellers 5 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 12.11%. About 46,428 shares traded hands. Calithera Biosciences Inc (NASDAQ:CALA) has declined 40.41% since April 25, 2016 and is downtrending. It has underperformed by 46.43% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $70.49 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Insitutional Activity: The institutional sentiment increased to 0.76 in 2016 Q2. Its up 0.29, from 0.47 in 2016Q1. The ratio improved, as 16 funds sold all Calithera Biosciences Inc shares owned while 18 reduced positions. 9 funds bought stakes while 7 increased positions. They now own 7.04 million shares or 18.29% less from 8.61 million shares in 2016Q1.
Fmr Limited Com holds 2.00M shares or 0% of its portfolio. Moreover, Jpmorgan Chase And Company has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 1,061 shares. Blackrock Investment Management Llc owns 2,467 shares or 0% of their US portfolio. Blackrock Institutional Trust Com Na reported 230,825 shares or 0% of all its holdings. Alpine Prns Vi Lc has 15,495 shares for 0.03% of their US portfolio. The North Carolina-based State Bank Of America De has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Paloma Partners Mngmt Co has 0% invested in the company for 40,338 shares. Adage Cap Lc holds 3.14 million shares or 0.03% of its portfolio. First Eagle Invest Mngmt Limited Liability Corp accumulated 205,369 shares or 0% of the stock. Wells Fargo And Mn owns 53,405 shares or 0% of their US portfolio. Gsa Cap Prtn Limited Liability Partnership accumulated 0.01% or 43,800 shares. Deutsche National Bank Ag has 0% invested in the company for 20,581 shares. Susquehanna Grp Ltd Liability Partnership, a Pennsylvania-based fund reported 27,090 shares. Goldman Sachs Gp accumulated 24,458 shares or 0% of the stock. Tower Capital Lc (Trc) last reported 0% of its portfolio in the stock.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Out of 3 analysts covering Calithera Biosciences (NASDAQ:CALA), 2 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive. Calithera Biosciences has been the topic of 4 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was initiated by Citigroup on Tuesday, October 25 with “Sell”. The company was initiated on Friday, July 24 by Citigroup. JMP Securities maintained it with “Market Outperform” rating and $12 target price in Wednesday, March 9 report.

CALA Company Profile

Calithera Biosciences, Inc., incorporated on March 9, 2010, is a clinical-stage pharmaceutical company. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Firm is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. The Company’s other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. The Company’s lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target.

More recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Quotes.Wsj.com which released: “News Calithera Biosciences Inc.CALA” on February 17, 2011. Also Equitiesfocus.com published the news titled: “Calithera Biosciences, Inc. (NASDAQ:CALA) Quarterly EPS From Continuing …” on November 28, 2016. Prnewswire.com‘s news article titled: “ProTrials Research, Inc. Selected by Calithera Biosciences, Inc. for Early …” with publication date: July 25, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>